Prostate Cancer

Prostate Cancer – High‑Yield Study Guide for Medical Students

Definition

Prostate cancer is a malignant epithelial tumor arising most commonly from the glandular cells of the prostate (adenocarcinoma). It is typically androgen-dependent and often develops in the peripheral zone, which is why many tumors are palpable on digital rectal examination (DRE). Aggressiveness is graded by the Gleason score / Grade Group system, and risk stratification guides management.

Epidemiology

Prostate cancer is one of the most commonly diagnosed cancers in men globally and a leading cause of cancer-related mortality in males, particularly in high-income countries.^{[5](https://pubmed.ncbi.nlm.nih.gov/41681930/)}

• Age: Incidence rises sharply after age 50; most cases present in the 6th–8th decades.
• Race/ethnicity: Higher incidence and mortality in Black men; lower in Asian populations.
• Geography: Higher in North America, Northern/Western Europe; lower in Asia and Africa (partly screening and reporting related).
• Family history: First-degree relative with prostate cancer increases risk and lowers age at onset.
• Genetic predisposition: BRCA2, HOXB13 and other germline variants confer increased risk and more aggressive disease.
• Environmental / lifestyle factors: Diet high in saturated fat and obesity are associated with more advanced disease; endocrine-disrupting chemicals (e.g., phthalates such as DEHP and its metabolite MEHP) are being investigated for roles in carcinogenesis and progression.^{[1](https://pubmed.ncbi.nlm.nih.gov/41828070/)}

Pathophysiology

Prostate carcinogenesis is a multistep process involving genetic, epigenetic, hormonal, and environmental factors. Tumors are typically adenocarcinomas developing from prostatic intraepithelial neoplasia (PIN) in the peripheral zone.

• Androgen signaling: Androgens (testosterone, dihydrotestosterone) bind to androgen receptors (AR), driving proliferation and survival of prostate epithelial cells. Most prostate cancers retain dependence on AR signaling, which is why androgen deprivation therapy (ADT) is effective in advanced disease.
• Genetic changes: Common alterations include TMPRSS2-ERG gene fusion, PTEN loss, and other tumor suppressor gene defects. These contribute to uncontrolled growth and invasion.
• Microenvironment and progression: Tumor progression involves changes in immune surveillance and inflammatory signaling; experimental models suggest that agents such as sulforaphane can modulate immune responses and reduce tumor development, underscoring the role of the tumor–immune microenvironment.^{[2](https://pubmed.ncbi.nlm.nih.gov/41802185/)}
• Metastatic pattern: Prostate cancer often spreads via lymphatics to pelvic and para-aortic nodes and hematogenously to bone (classically osteoblastic lesions), followed by lung and liver.
• Endocrine disruptors: Emerging evidence suggests that prolonged exposure to phthalates (e.g., DEHP/MEHP) may promote aggressive phenotypes via ion channel and signaling pathway modulation, potentially influencing progression and prognosis.^{[1](https://pubmed.ncbi.nlm.nih.gov/41828070/)}

Clinical Presentation

Many patients with early-stage prostate cancer are asymptomatic and diagnosed via PSA testing and/or DRE performed for screening or evaluation of lower urinary tract symptoms (LUTS).

• Local disease:
  • Often asymptomatic.
  • May cause LUTS similar to BPH: hesitancy, weak stream, frequency, nocturia.
  • Hematospermia or hematuria in some cases.
  • DRE findings: classically a hard, nodular, or asymmetric prostate, typically in the peripheral zone.
• Locally advanced disease:
  • Obstructive urinary symptoms (acute urinary retention less common).
  • Perineal pain, pelvic discomfort.
  • Possible involvement of neurovascular bundles leading to erectile dysfunction.
• Metastatic disease:
  • Bone pain (e.g., spine, pelvis, ribs) from osteoblastic metastases.
  • Pathologic fractures.
  • Spinal cord compression symptoms: back pain, weakness, bowel/bladder dysfunction.
  • Constitutional symptoms in advanced disease: weight loss, fatigue.

Diagnosis

Diagnosis integrates PSA testing, DRE, imaging, and histopathology. Biopsy is required for definitive diagnosis.

Screening and Initial Evaluation

• PSA (prostate-specific antigen):
  • Organ-specific but not cancer-specific; elevated in BPH, prostatitis, urinary retention.
  • Used for screening and monitoring response to therapy.
  • Interpretation may incorporate age-specific ranges, PSA velocity, and PSA density.
• DRE:
  • Palpation of the posterior prostate via the rectum.
  • Findings suggesting malignancy: focal induration, nodules, asymmetry, or "rock-hard" texture.
• Screening practices:
  • Use of PSA and DRE for screening remains controversial and varies by guideline and region.
  • Medical students often have gaps in knowledge about appropriate screening; targeted education is important to optimize future practice.^{[7](https://europepmc.org/article/MED/41572262)}

Confirmatory Testing

• Multiparametric MRI (mpMRI):
  • Now standard in many centers before biopsy to localize suspicious lesions and guide targeted biopsy.
  • Provides information about extraprostatic extension (EPE), seminal vesicle invasion, and overall tumor burden, which is critical for surgical planning and nerve-sparing decisions.^{[5](https://pubmed.ncbi.nlm.nih.gov/41681930/)}
• Prostate biopsy:
  • Transrectal or transperineal ultrasound-guided biopsies, often 10–12 core systematic sampling plus targeted cores based on mpMRI lesions.
  • Histology typically shows adenocarcinoma with small crowded glands lacking basal cells, prominent nucleoli.
  • Gleason grading / Grade Group: pattern-based system (3–5) combined into a score (e.g., 3+4=7) and translated into Grade Groups (1–5) for risk stratification.
  • Novel computational pathology approaches (e.g., multiple instance learning models) are being explored to improve accuracy and reproducibility of Gleason/Grade Group prediction from whole-slide images.^{[6](https://europepmc.org/article/MED/41762944)}

Staging

Staging uses the TNM system, PSA level, and Gleason Grade Group to classify into risk groups and guide treatment.

• T stage: based on DRE and imaging (T1: non-palpable; T2: confined to prostate; T3: extraprostatic extension/seminal vesicle invasion; T4: invasion of adjacent structures).
• N stage: pelvic lymph node involvement assessed by imaging and sometimes surgical lymph node dissection.
• M stage: distant metastases, commonly to bone.
• Imaging for staging:
  • ct/MRI pelvis for local staging and nodal evaluation.
  • Bone scan or nuclear imaging if high-risk or symptomatic.
  • PSMA PET/CT: Prostate-specific membrane antigen PET has high sensitivity and specificity for detecting nodal and distant metastases and is increasingly used in staging and treatment planning; quantitative PSMA PET biomarkers are also used in predicting response to PSMA-targeted radioligand therapy.^{[3](https://pubmed.ncbi.nlm.nih.gov/41748296/)}

Management

Management is individualized based on risk stratification, life expectancy, comorbidities, and patient preferences. Broad categories include localized, locally advanced, and metastatic disease.

Management of Localized Disease

• Active surveillance (AS):
  • Appropriate for very low- and low-risk disease (e.g., PSA <10, Grade Group 1, limited core involvement, low-volume tumors).
  • Involves regular PSA, DRE, repeat imaging and biopsies; curative treatment is initiated if progression is documented.
• Radical prostatectomy (RP):
  • Removal of the prostate gland, seminal vesicles, and often pelvic lymph nodes (especially in intermediate- and high-risk disease).
  • Open, laparoscopic, or robot-assisted approaches.
  • Nerve-sparing techniques are used when oncologically safe to preserve erectile function; accurate preoperative detection of extraprostatic extension (via mpMRI and clinical factors) is key to deciding on nerve-sparing.^{[5](https://pubmed.ncbi.nlm.nih.gov/41681930/)}
  • Complications: urinary incontinence, erectile dysfunction, lymphoceles; peritoneal flaps and other techniques can reduce lymphocele formation after robot-assisted RP.^{[9](https://europepmc.org/article/MED/41733695)}
• Radiation therapy (RT):
  • External beam radiation therapy (EBRT) and/or brachytherapy.
  • Equivalent oncologic outcomes to RP for many risk categories.
  • Side effects: radiation cystitis, proctitis, erectile dysfunction, urinary frequency, secondary malignancies in the long term.
  • Intermediate- and high-risk patients often receive EBRT plus short- or long-term ADT.

Management of Locally Advanced Disease

• Combined-modality therapy:
  • EBRT plus long-term ADT is standard for many patients with T3/T4 or high-risk disease.
  • RP with extended lymph node dissection may be offered to highly selected patients with locally advanced disease as part of multimodal therapy.
• ADT strategies:
  • LHRH agonists or antagonists with or without first-generation antiandrogens.
  • Goal is castrate levels of testosterone and suppression of AR signaling.

Management of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

• Systemic ADT: backbone of therapy.
• Intensification:
  • Addition of docetaxel or novel androgen receptor signaling inhibitors (e.g., abiraterone, enzalutamide, apalutamide) improves survival compared with ADT alone.
  • Choice depends on disease volume, comorbidities, and patient preference.
• Local treatment to the prostate:
  • In low-volume metastatic disease, RT to the primary prostate tumor (in addition to systemic therapy) may confer survival benefit according to some trials.

Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

• Definition: Disease progression (radiographic or PSA) despite castrate levels of testosterone.
• Treatment options:
  • Next-generation AR pathway inhibitors (enzalutamide, abiraterone) if not previously used.
  • Chemotherapy (docetaxel, cabazitaxel) for symptomatic or visceral disease.
  • Bone-targeted agents: bisphosphonates or denosumab for prevention of skeletal-related events.
  • Radium-223 dichloride for symptomatic bone-predominant disease without visceral metastases.
  • PSMA-targeted radioligand therapy (Lu-PSMA-617): Lutetium-177–labeled PSMA ligands deliver targeted beta radiation to PSMA-expressing tumor cells; PSMA PET biomarkers help select candidates and predict response to this therapy.^{[3](https://pubmed.ncbi.nlm.nih.gov/41748296/)}
  • PARP inhibitors (e.g., olaparib) in patients with homologous recombination repair gene mutations.
• Palliative care: Pain control, management of spinal cord compression, and supportive care are essential components at advanced stages.

Prevention and Risk Reduction

• Primary prevention:
  • No proven chemopreventive agent routinely recommended.
  • Healthy diet, weight control, and physical activity may reduce risk of aggressive disease.
  • Experimental data suggest that compounds such as sulforaphane can modulate immune surveillance and suppress prostate cancer development in preclinical models, but clinical applications are not yet standard.^{[2](https://pubmed.ncbi.nlm.nih.gov/41802185/)}
  • Minimizing exposure to potential endocrine-disrupting chemicals (e.g., certain phthalates) is an area of ongoing research rather than guideline-based recommendation.^{[1](https://pubmed.ncbi.nlm.nih.gov/41828070/)}
• Secondary prevention:
  • Shared decision-making around PSA-based screening, especially in men with increased risk (e.g., strong family history, Black race).

Key Clinical Pearls for Medical Students

• 1. Prostate cancer is common and often silent: Many men harbor indolent disease; understanding the balance between overdiagnosis and underdiagnosis is crucial.
• 2. PSA is a tool, not a diagnosis: Elevated PSA requires contextual interpretation (age, prostate volume, infection/inflammation) and usually confirmation before biopsy.
• 3. DRE remains important: Despite the rise of PSA and imaging, DRE is still vital in detecting palpable nodules and should be part of the exam skillset; studies show medical students often lack confidence and knowledge about DRE and PSA, emphasizing the need for early training.^{[7](https://europepmc.org/article/MED/41572262)}
• 4. mpMRI now shapes biopsy and surgery: mpMRI improves detection of clinically significant cancer, guides targeted biopsies, and helps assess extraprostatic extension, influencing nerve-sparing and margin strategies.^{[5](https://pubmed.ncbi.nlm.nih.gov/41681930/)}
• 5. Risk stratification drives therapy: Always think in terms of low-, intermediate-, high-risk localized, locally advanced, and metastatic disease when considering treatment options.
• 6. Active surveillance is not "doing nothing": For low-risk disease, AS with structured follow-up can safely avoid or defer treatment-related morbidity in many patients.
• 7. ADT has systemic effects: Monitor for osteoporosis, metabolic syndrome, cardiovascular risk, and quality-of-life issues when patients are on long-term ADT.
• 8. mCRPC is increasingly treatable: Multiple agents targeting androgen signaling, bone microenvironment, DNA repair, and PSMA are available; PSMA PET and radioligand therapy are rapidly evolving areas in advanced prostate cancer care.^{[3](https://pubmed.ncbi.nlm.nih.gov/41748296/)}
• 9. Surgical complications can often be mitigated: Techniques such as peritoneal flaps during robot-assisted radical prostatectomy can reduce postoperative lymphoceles, improving recovery.^{[9](https://europepmc.org/article/MED/41733695)}
• 10. Stay updated: Prostate cancer is a fast-moving field with ongoing advances in imaging (PSMA PET), systemic therapy, and biomarker-driven management; continuous learning is essential.